Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.65 |
| ▸ | MEN1 | O00255 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.65 |
| ▸ | POLB | P06746 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | GMNN | O75496 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | THPO | P40225 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5708853 | 0.94 | MEN1 (0.75) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL5708805 | 0.85 | KMT2A (0.87) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL31657803 | 0.85 | KMT2A (0.69) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL31657800 | 0.85 | KMT2A (0.87) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL19376052 | 0.85 | KMT2A (0.69) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL31657826 | 0.85 | KMT2A (0.77) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL12686266 | 0.85 | KMT2A (0.77) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL5708842 | 0.84 | MEN1 (0.50) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL31657812 | 0.81 | MEN1 (0.67) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL5708728 | 0.81 | MEN1 (0.67) | KMT2AMEN1ALDH1A1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358909-B2 | Capsazepine analogs for the treatment of cancer and other proliferative diseases | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-07-15 | — | — | US | disclosed |
| US-10457676-B2 | Capsazepine analogs for the treatment of cancer and other proliferative diseases | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457676-B2 | Capsazepine analogs for the treatment of cancer and other proliferative diseases | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-29 | — | — | US | disclosed |
| EP-3549582-A2 | NOVEL CAPSAZEPINE ANALOGS FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | The Board of Regents of The University of Texas System (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-3549582-A2 | NOVEL CAPSAZEPINE ANALOGS FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | The Board of Regents of The University of Texas System (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20170275280-A1 | NOVEL CAPSAZEPINE ANALOGS FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275280-A1 | NOVEL CAPSAZEPINE ANALOGS FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275280-A1 | NOVEL CAPSAZEPINE ANALOGS FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275280-A1 | NOVEL CAPSAZEPINE ANALOGS FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | TRPV1, TRPV5, CNR2 | KMT2A 2918/4885MEN1 3654/4885ALDH1A1 2243/4885 |
| US-12358909-B2 | Capsazepine analogs for the treatment of cancer and other proliferative diseases | TRPV1, CNR2, GPR17 | KMT2A 2658/4885MEN1 3319/4885ALDH1A1 2371/4885 |
| US-10457676-B2 | Capsazepine analogs for the treatment of cancer and other proliferative diseases | TRPV1, TRPV5, CNR2 | KMT2A 2511/4885MEN1 3228/4885ALDH1A1 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.